Prospective Phase II Trial of Cemiplimab Plus Gemcitabine in SWItch/Sucrose Nonfermentable-Altered Metastatic Pancreatic Ductal Adenocarcinoma
Open Access
- 1 July 2026
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (3)
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Gemcitabine: immunomodulatory or immunosuppressive role in the tumor microenvironmentFrontiers in Immunology, 2025
- ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunityCell, 2024
- SWI/SNF chromatin remodeling complex in pancreatic ductal adenocarcinoma: Clinicopathologic and immunohistochemical studyHuman Pathology, 2024
- Therapeutic developments in pancreatic cancerNature Reviews Gastroenterology & Hepatology, 2023
- SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancerJCI Insight, 2021
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeuticsThe Lancet Oncology, 2017
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989